- Home
- ASC vs ERAS Comparison
ASC vs ERAS Comparison
Compare ASC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASC | ERAS |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.7M | 1.0B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ASC | ERAS |
|---|---|---|
| Price | $14.14 | $13.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $15.00 | $10.25 |
| AVG Volume (30 Days) | 805.4K | ★ 3.6M |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.32 | $1.01 |
| 52 Week High | $16.91 | $16.14 |
Technical Indicators
Market Signals| Indicator | ASC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 48.37 |
| Support Level | $10.42 | $1.50 |
| Resistance Level | $16.91 | $16.14 |
| Average True Range (ATR) | 0.61 | 1.00 |
| MACD | -0.36 | -0.38 |
| Stochastic Oscillator | 20.57 | 2.55 |
Price Performance
Historical ComparisonAbout ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.